Development of a multiple sclerosis functional composite as a clinical trial outcome measure

Brain

Volumn 122, Issue 5, 1999, Pages 871-882

  Cutter, Gary R ^a   Baier, Monika L ^a   Rudick, Richard A ^b   Cookfair, Diane L ^c   Fischer, Jill S ^b   Petkau, John ^k   Syndulko, Karl ^f   Weinshenker, Brian G ^h   Antel, Jack P ^l   Confavreux, Christian ^m   Ellison, George W ^g   Lublin, Fred ⁱ   Miller, Aaron E ^d   Rao, Stephen M ^j   Reingold, Stephen ^e   Thompson, Alan ⁿ   Willoughby, Ernest ^o  

^a UNIVERSITY OF COLORADO   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d MAIMONIDES MEDICAL CENTER   (United States)

^e National Multiple Sclerosis Society   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g UCLA MEDICAL CENTER   (United States)

^h MAYO CLINIC   (United States)

ⁱ DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^j MCW Clinic at Froedtert   (United States)

^k UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^l MCGILL UNIVERSITY   (Canada)

^m Hopital de l'Antiquaille   (France)

ⁿ NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^o AUCKLAND CITY HOSPITAL   (New Zealand)

more..

Author keywords

Multiple sclerosis clinical outcome measure

Indexed keywords

ARM MOVEMENT; ARTICLE; COGNITION; DISABILITY; HUMAN; LEG MOVEMENT; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RATING SCALE; SAMPLE; TREATMENT OUTCOME;

CLINICAL TRIALS; DISABILITY EVALUATION; HUMANS; MULTIPLE SCLEROSIS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SAMPLING STUDIES; TREATMENT OUTCOME;

EID: 0032919071     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/122.5.871     Document Type: Article

References (52)

1. Brooks BR, Lewis D, Rawling J, Sanjak M, Belden D, Hakim H, et al. The natural history of amyotrophic lateral sclerosis. In: Williams AC, editor. Motor neuron disease. London: Chapman & Hall; 1994. p. 131-169.
2. Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis [see comments]. Lancet 1991; 337: 441-6.
3. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 1980; 103: 281-300.
4. Conover WJ. Practical nonparametric statistics. 2nd ed. New York: John Wiley; 1980.
5. Desrosiers J, Bravo G, Hebert R, Dutil E, Mercier L. Validation of the Box and Block Test as a measure of dexterity of elderly people: reliability, validity, and norms studies. Arch Phys Med Rehabil 1994; 75: 751-5.
6. Ellison GW, Myers LW, Mickey MR, Graves MC, Tourtellotte WW, Syndulko K, et al. A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis. Neurology 1989; 39: 1018-26.
7. Ellison GW, Myers LW, Leake BD, Mickey MR, Ke D, Syndulko K, et al. Design strategies in multiple sclerosis clinical trials. The Cyclosporine Multiple Sclerosis Study Group. Ann Neurol 1994; 36 Suppl: S108-12.
8. Fischer J, Jack AJ, Kniker JE, Cutter G, National Multiple Sclerosis Society Outcome Assessment Task Force. Administration and Scoring Manual for the Multiple Sclerosis Functional Composite. Demos Publications, New York. In press 1999.
9. Goldsmith CH, Smythe HA, Helewa A. Interpretation and power of a pooled index. J Rheumatol 1993; 20: 575-8.
10. Goodkin DE, Hertsgaard D, Seminary J. Upper extremity function in multiple sclerosis: improving assessment sensitivity with Box-and-Block and Nine-Hole Peg Tests. Arch Phys Med Rehabil 1988; 69: 850-4.
11. Goodkin DE, Bailly RC, Teetzen ML, Hertsgaard D, Beatty WW. The efficacy of azathioprine in relapsing-remitting multiple sclerosis. Neurology; 1991, 41: 20-5.
12. Goodkin DE, Rudick RA, VanderBrug Medendorp S, Daughtry MM, Schwetz KM, Fischer J, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis [see comments]. Ann Neurol 1995; 37: 30-40. Comment in: Ann Neurol 1995; 37: 5-6, Comment in: Ann Neurol 1995; 38: 832-3, Comment in: Ann Neurol 1996; 39: 684.
13. Goodkin DE, Rudick RA, VanderBrug Medendorp S, Daughtry MM, Schwetz KM, Fischer J, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis [see comments]. Ann Neurol 1995; 37: 30-40. Comment in: Ann Neurol 1995; 37: 5-6, Comment in: Ann Neurol 1995; 38: 832-3, Comment in: Ann Neurol 1996; 39: 684.
14. Goodkin DE, Rudick RA, VanderBrug Medendorp S, Daughtry MM, Schwetz KM, Fischer J, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis [see comments]. Ann Neurol 1995; 37: 30-40. Comment in: Ann Neurol 1995; 37: 5-6, Comment in: Ann Neurol 1995; 38: 832-3, Comment in: Ann Neurol 1996; 39: 684.
15. Goodkin DE, Rudick RA, VanderBrug Medendorp S, Daughtry MM, Schwetz KM, Fischer J, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis [see comments]. Ann Neurol 1995; 37: 30-40. Comment in: Ann Neurol 1995; 37: 5-6, Comment in: Ann Neurol 1995; 38: 832-3, Comment in: Ann Neurol 1996; 39: 684.
16. Gronwall DMA. Paced auditory serial-addition task: a measure of recovery from concussion. Percept Mot Skills 1977; 44: 367-73.
17. Hauser SL, Dawson DM, Lehrich JR, Beal MF, Kevy SV, Propper RD, et al. Intensive immunosuppression in progressive multiple sclerosis: a randomized three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983; 308: 173-80.
18. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial [see comments]. Neurology 1993; 43: 655-61. Comment in: Neurology 1993; 43: 641-3.
19. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial [see comments]. Neurology 1993; 43: 655-61. Comment in: Neurology 1993; 43: 641-3.
20. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis [see comments] [published erratum appears in Ann Neurol 1996; 40: 480]. Ann Neurol 1996; 39(3): 285-294. Comment in: ACP J Club 1996; 125: 35, Comment in: Ann Neurol 1996; 40: 951-3, Comment in: Ann Neurol 1997; 41: 560, Comment in: Ann Neurol 1997; 42: 982.
21. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis [see comments] [published erratum appears in Ann Neurol 1996; 40: 480]. Ann Neurol 1996; 39(3): 285-294. Comment in: ACP J Club 1996; 125: 35, Comment in: Ann Neurol 1996; 40: 951-3, Comment in: Ann Neurol 1997; 41: 560, Comment in: Ann Neurol 1997; 42: 982.
22. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis [see comments] [published erratum appears in Ann Neurol 1996; 40: 480]. Ann Neurol 1996; 39(3): 285-294. Comment in: ACP J Club 1996; 125: 35, Comment in: Ann Neurol 1996; 40: 951-3, Comment in: Ann Neurol 1997; 41: 560, Comment in: Ann Neurol 1997; 42: 982.
23. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis [see comments] [published erratum appears in Ann Neurol 1996; 40: 480]. Ann Neurol 1996; 39(3): 285-294. Comment in: ACP J Club 1996; 125: 35, Comment in: Ann Neurol 1996; 40: 951-3, Comment in: Ann Neurol 1997; 41: 560, Comment in: Ann Neurol 1997; 42: 982.
24. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis [see comments] [published erratum appears in Ann Neurol 1996; 40: 480]. Ann Neurol 1996; 39(3): 285-294. Comment in: ACP J Club 1996; 125: 35, Comment in: Ann Neurol 1996; 40: 951-3, Comment in: Ann Neurol 1997; 41: 560, Comment in: Ann Neurol 1997; 42: 982.
25. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis [see comments] [published erratum appears in Ann Neurol 1996; 40: 480]. Ann Neurol 1996; 39(3): 285-294. Comment in: ACP J Club 1996; 125: 35, Comment in: Ann Neurol 1996; 40: 951-3, Comment in: Ann Neurol 1997; 41: 560, Comment in: Ann Neurol 1997; 42: 982.
26. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group [see comments]. Neurology 1995; 45: 1268-76. Comment in: Neurology 1995; 45: 1245-7, Comment in: ACP J Club 1996; 124: 2-3.
27. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group [see comments]. Neurology 1995; 45: 1268-76. Comment in: Neurology 1995; 45: 1245-7, Comment in: ACP J Club 1996; 124: 2-3.
28. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group [see comments]. Neurology 1995; 45: 1268-76. Comment in: Neurology 1995; 45: 1245-7, Comment in: ACP J Club 1996; 124: 2-3.
29. Kurtzke JF. A new scale for evaluating disability in multiple sclerosis. Neurology 1955; 5: 580-3.
30. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
31. Mathiowetz V, Weber K, Kashman N, Volland G. Adult norms for 9 Hole Peg Test of finger dexterity. Occup Ther J Res 1985a; 5: 24-38.
32. Mathiowetz V, Volland G, Kashman N, Weber K. Adult norms for Box and Block Test of manual dexterity. Am J Occup Ther 1985b; 39: 386-91.
33. Multiple Sclerosis Study Group. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial [see comments]. Ann Neurol 1990; 27: 591-605. Comment in: Ann Neurol 1991; 29: 226.
34. Multiple Sclerosis Study Group. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial [see comments]. Ann Neurol 1990; 27: 591-605. Comment in: Ann Neurol 1991; 29: 226.
35. Paty D, Studney D, Redekop K, Lublin F. MS COSTAR: a computerized patient record adapted for clinical research purposes. Ann Neurol 1994; 36 Suppl: S134-35.
36. Potvin AR, Tourtellotte WW. Quantitative examination of neurologic function. Volume II. Methodology for test and patient assessments and design of a computer-automated system. Boca Raton (FL): CRC Press; 1985.
37. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction [see comments]. Neurology 1991; 41: 685-91. Comment in: Neurology 1991; 41: 2014-5
38. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction [see comments]. Neurology 1991; 41: 685-91. Comment in: Neurology 1991; 41: 2014-5
39. Rudick RA, Medendorp SV, Namey M, Boyle S, Fischer J. Multiple sclerosis progression in a natural history study: predictive value of cerebrospinal fluid free kappa light chains. Mult Scler 1995; 1: 150-5.
40. Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, et al. Clinical outcomes assessment in multiple sclerosis. [Review]. Ann Neurol 1996; 40: 469-79.
41. Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, et al. Recommendations from the National Multiple Sclerosis Society Clinical Outcome Assessment Task Force. Ann Neurol 1997, 42: 379-82.
42. Schwid SR, Goodman AD, Mattson DH, Mihai C, Donohoe KM, Petrie MD, et al. The measurement of ambulatory impairment in multiple sclerosis. Neurology 1997; 49: 1419-24.
43. Sipe JC, Knobler RL, Braheny SL, Rice GP. Panitch HS, Oldstone MB. A neurologic rating scale (NRS) for use in multiple sclerosis. Neurology 1984; 34: 1368-72.
44. Smith A. Symbol-Digit Modalities Test Manual. Los Angeles: Western Psychological Services; 1973.
45. Syndulko K, Ke D, Ellison GW, Baumhefner RW, Myers LW, Tourtellotte WW, and the Multiple Sclerosis Study Group. Comparative evaluations of neuroperformance and clinical outcome assessments in chronic progressive multiple sclerosis. I. Reliability, validity and sensitivity to disease progression. Mult Scler 1996; 2: 142-56.
46. Tourtellotte WW, Haerer AF, Simpson JF, Kuzma JW, Sikorski J. Quantitative clinical neurological testing. I. A study of a battery of tests designed to evaluate in part the neurological function of patients with multiple sclerosis and its use in a therapeutic trial. Ann NY Acad Sci 1965; 122: 480-505.
47. Weiner HL, Dau PC, Khatri BO Petajan JH, Birnbaum G, McQuillen MP, et al. Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis [see comments]. Neurology 1989; 39: 1143-9. Comment in: Neurology 1990; 40: 864-6.
48. Weiner HL, Dau PC, Khatri BO Petajan JH, Birnbaum G, McQuillen MP, et al. Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis [see comments]. Neurology 1989; 39: 1143-9. Comment in: Neurology 1990; 40: 864-6.
49. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study 1. Clinical course and disability. Brain 1989; 112: 133-46.
50. Weinshenker BG, Issa M, Baskerville J. Meta-analysis of the placebo-treated groups in clinical trials of progressive MS. Neurology 1996; 46: 1613-9.
51. Whitaker JN, McFarland HF, Rudge P, Reingold SC. Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Mult Scler 1995; 1: 37-17.
52. Wiens AN, Fuller KH, Crossen JR. Paced Auditory Serial Addition Test: adult norms and moderator variables. J Clin Exp Neuropsychol 1997; 19: 473-83.